BioNTech AG and Pfizer Inc., initiate a phase 1/II trial of BNT 162 vaccine to prevent COVID-19 infection.
BioNTech AG and Pfizer Inc. have announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/II clinical trial for BioNTech’s BNT 162 vaccine program to… read more.